Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

Executive Summary

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.


Related Content

iTeos Says Adios To IDO And Eyes US IPO
Immuno-Oncology: What To Watch At ASCO 2018
More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod
Merck's Keytruda Keeps Nipping At Opdivo's Heels
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Scrip's Rough Guide To IDO
Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial
Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn
NewLink-Genentech deal could be worth more than $1bn

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts